[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100415910":3},{"organization":4,"outcomesModule":7,"designInfo":38,"detailedDescription":37,"studyPopulation":37,"armGroups":44,"interventions":53,"overallOfficials":37,"centralContacts":59,"locations":65,"responsibleParty":81,"collaborators":37,"id":83,"slug":37,"hasResults":84,"nctId":85,"briefTitle":86,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":84,"sex":89,"minAge":90,"maxAge":37,"enrollmentInfo":91,"targetDuration":37,"studyType":94,"phases":95,"briefSummary":97,"conditions":98,"keywords":37,"overallStatus":68,"whyStopped":37,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},{"fullName":5,"class":6},"University of Aarhus","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":17,"otherOutcomes":37},[9,13],{"measure":10,"description":11,"timeFrame":12},"R0-resection","Neo-adjuvant treatment: Rate of pathological complete resection (R0)","5-6 years",{"measure":14,"description":15,"timeFrame":16},"1-year local control","Definitive treatment: Rate of 1-year local control rates evaluated by CT or MRI.","6-7 years",[18,22,26,29,33],{"measure":19,"description":20,"timeFrame":21},"Local recurrence","Local re-recurrence determined by imaging 6, 12 and 24 month post treatment","6-8 years",{"measure":23,"description":24,"timeFrame":25},"Disease free survival","Disease free survival, defined as time from first day of treatment until first documented sign of disease or death from any course","10 years",{"measure":27,"description":28,"timeFrame":25},"Overall survival","Overall survival defined as time from first day of treatment to death from any cause",{"measure":30,"description":31,"timeFrame":32},"Toxicity","Toxicity evaluated by NCI-CTCAE v. 5.0 acute and chronic","5-7 years",{"measure":34,"description":35,"timeFrame":36},"Patient reported outcomes","Quality of life assessment by EORTC QLQ-c30, QLQ-CR29, supplementary EORTC items, and LARS score. Acute and chronic","5-7 year",null,{"allocation":39,"interventionModel":40,"interventionModelDescription":37,"primaryPurpose":41,"observationalModel":37,"timePerspective":37,"maskingInfo":42},"NON_RANDOMIZED","SINGLE_GROUP","TREATMENT",{"masking":43,"maskingDescription":37,"whoMasked":37},"NONE",[45,50],{"label":46,"type":47,"description":37,"interventionNames":48},"Neo-adjuvant pencil beam proton therapy: 55 Gy(RBE)\u002F44fx (1.25 Gy per fraction), two daily","EXPERIMENTAL",[49],"Radiation: Pencil beam proton radiotherapy",{"label":51,"type":47,"description":37,"interventionNames":52},"Definitive arm pencil beam proton therapy: 57.5-65Gy(RBE)\u002F46-52 fx (1.25 per fraction) two daily",[49],[54],{"type":55,"name":56,"description":57,"armGroupLabels":58,"otherNames":37},"RADIATION","Pencil beam proton radiotherapy","Doseescalated pencil beam proton Therapy",[51,46],[60],{"name":61,"role":62,"phone":63,"phoneExt":37,"email":64},"Camilla Kronborg, MD, PhD","CONTACT","+45 78450000","camkro@rm.dk",[66],{"facility":67,"status":68,"city":69,"state":37,"zip":70,"country":71,"countryCode":72,"cosmosGeoPoint":73,"geoPoint":78,"contacts":79},"Danish Centre for Particle Therapy","RECRUITING","Aarhus","8200","Denmark","DK",{"type":74,"coordinates":75},"Point",[76,77],10.21076,56.15674,{"lat":77,"lon":76},[80],{"name":61,"role":62,"phone":37,"phoneExt":37,"email":37},{"type":82,"investigatorFullName":37,"investigatorTitle":37,"investigatorAffiliation":37,"oldNameTitle":37,"oldOrganization":37},"SPONSOR","100415910",false,"NCT04695782","Pencil Beam Proton Therapy for Pelvic Recurrences in Rectal Cancer Patients Previously Treated With Radiotherapy","ReRad II","Inclusion Criteria:\n\n* • Locally recurrent rectal cancer.\n\n  * Bioptically verified (adenocarcinoma )\n  * Available dose plan from primary radiotherapy\n  * Previous pelvic RT (\\>30Gy EQD2)\n  * Evaluated in MDT-conferences (Herlev, Aarhus)\n  * Age\\>18 years\n  * PS 0-2\n  * Adequate organ function\n  * Informed consent\n\nExclusion Criteria:\n\n* Non-resectable distant metastases (PET-CT)\n* Unable to undergo MRI, PET-CT\n* Inability to attend full course radiotherapy and follow up in the out patient clinic.","ALL","18 Years",{"count":92,"type":93},65,"ESTIMATED","INTERVENTIONAL",[96],"PHASE2","Study design:\n\nA prospective phase II, non-randomized observational study of dose-escalated pencil beam proton therapy re-irradiation for pelvic recurrences from rectal cancer.\n\nRe-irradiation is either a part of neo-adjuvant treatment or as a definitive treatment strategy for un-resectable recurrences.",[99],"Rectal Cancer Recurrent","2021-01-04",{"date":102,"type":103},"2021-01-05","ACTUAL",{"date":105,"type":103},"2020-10-10",{"date":107,"type":93},"2028-10-31",{"name":5,"class":6},1]